Agoraphobia Treatment Market

Some 54.6 million adults worldwide live with past-year agoraphobia in the Douglas Insights model, yet only about 15.1 million of them receive a single year of care. The Agoraphobia Treatment Market covers the medicines, talking therapies and digital tools used to treat agoraphobia, a fear of places where escape feels hard, and it includes SSRIs, benzodiazepines, cognitive behavioural therapy, exposure therapy and virtual reality (VR) programmes. Douglas Insights estimates the market at USD 2.21 billion in 2025, built as 15.07 million treated patient-years times USD 146.8 of average spend per patient-year, and expects USD 3.15 billion by 2035, a 3.58% revenue CAGR. The gap between those two head counts is the story: the World Health Organization fact sheet updated on 15 September 2026 says only 27.6% of people with an anxiety disorder receive any treatment. The study belongs to our pharmaceuticals coverage, and every step of the build follows our research methodology.

Which agoraphobia treatment type makes the money: exposure therapy, SSRIs or benzodiazepines?

Cognitive behavioural therapy and exposure therapy lead the agoraphobia treatment market with a 36.2% share, worth USD 801.0 million in 2025, because a full therapy course costs many times a year of generic tablets. SSRI and SNRI antidepressants follow at 34.7%, and the two first-line routes together hold 70.9% of value.

Cognitive behavioural therapy and exposure therapy earn USD 801.0 million because a structured course of 12 or more sessions is priced per therapist hour, and graded exposure is the step that breaks agoraphobic avoidance. SSRI and SNRI antidepressants bring in USD 767.8 million: sertraline, escitalopram, paroxetine and venlafaxine are taken for 6 to 12 months, so volume is high even at generic prices. Benzodiazepines account for USD 305.4 million, a 13.8% slice that shrinks at 0.64% a year as prescribers taper alprazolam and clonazepam. Other medicines, mainly tricyclics, pregabalin and beta blockers used off label, add USD 230.1 million. Digital therapeutics and VR exposure are the smallest slice at USD 108.4 million.

Digital therapeutics and VR exposure grow fastest, at 13.4% a year to USD 381.3 million in 2035, lifting their share from 4.9% to 12.1%. The reason is reach: a headset or breathing sensor delivers exposure practice at home, the place a person with agoraphobia finds easiest to stay. Readers following software-led care can compare our Digital Medicine Market report.

Why are more panic and agoraphobia patients entering treatment each year?

Treated agoraphobia patient-years rise 2.62% a year to 2035, from 15.07 million to 19.52 million, because the treatment gap narrows, the adult population grows and telehealth removes the trip that agoraphobia itself blocks. Those three forces make up the whole volume leg of the agoraphobia treatment forecast.

A narrowing treatment gap adds 1.12 percentage points a year. The World Health Organization counted 470 million people with anxiety disorders in 2023 and reports that only about 1 in 4 people in need receive any treatment. Douglas Insights models the treated share of agoraphobia cases rising from 27.6% in 2025 to about 30.9% by 2035 as primary care screening, school mental health services and insurer parity rules widen. Each point of that treated share is worth roughly 546,000 extra patients in the current caseload of 54.6 million.

Adult population growth contributes 0.86 points. The United Nations puts the world at 8.2 billion people in 2024, and the adult cohort expands faster than the total because birth rates fall while survival improves. Prevalence sits at 0.9% of adults a year in the US National Comorbidity Survey Replication, with 40.6% of cases rated serious, so every additional 100 million adults brings about 900,000 people with past-year agoraphobia into the pool.

Remote care adds the last 0.64 points. More than 7 million controlled-medication prescriptions were issued by telemedicine in the United States in 2024, according to the HHS and DEA notice of 2 January 2026, which extended remote prescribing flexibilities through 31 December 2026. For agoraphobia the effect is larger than for most conditions, because the first visit to a clinic is often the very situation the patient avoids. Video CBT, app-based exposure homework and mailed prescriptions convert people who never would have walked into a waiting room. The same notice reports a 24% fall in fee-for-service telemedicine visits after Medicare flexibilities lapsed in September 2025, proof of how quickly that channel reacts to rule changes. Our Telehealth Market study tracks the wider channel.

The price leg adds a further 0.94% a year. Mix moves toward therapist-led and device-based care, which cost more per patient-year than generic SSRIs, while generic price erosion pulls tablets down. Douglas Insights expects average spend to climb from USD 146.8 to USD 161.2 per treated patient-year by 2035, a rise of USD 14.4 that comes almost entirely from therapy mix.

Which barriers keep agoraphobic avoidance untreated?

Three barriers hold the agoraphobia treatment volume leg at 2.62% instead of about 3.83%: therapist shortages remove 0.57 points, benzodiazepine deprescribing removes 0.38 points and the stigma of a housebound condition removes 0.26 points. Each figure is already netted out of the base case.

Therapist capacity is the tightest bottleneck, costing 0.57 points a year. A CBT course runs 12 to 16 weekly hours, so one full-time clinician treats only about 90 to 110 patients a year. Across much of Asia Pacific, Latin America and Africa, Douglas Insights finds trained CBT capacity far below need, which keeps agoraphobia care tablet-led even where guidelines prefer exposure therapy.

Benzodiazepine caution removes 0.38 points. On 23 September 2020 the US Food and Drug Administration required an updated Boxed Warning for every benzodiazepine, citing an estimated 92 million outpatient benzodiazepine prescriptions in 2019, 38% of them alprazolam. Prescribers now taper existing users and start fewer new ones, and not every tapered patient moves to an SSRI or to therapy.

Stigma and the condition itself remove 0.26 points. Agoraphobia keeps people at home, so the disorder suppresses its own diagnosis; NIMH data show 1.3% lifetime prevalence against 0.9% in any one year, a sign that many episodes pass without a recorded visit.

How much does a year of agoraphobia treatment cost, from generic sertraline to a CBT course?

Average agoraphobia treatment spend is USD 146.8 per treated patient-year in 2025, but realised prices span about 80 times. A year of generic SSRI tablets in India costs roughly USD 30, while a private CBT course in the United States reaches USD 2,400. Mix decides the blended figure.

Douglas Insights puts the realised bands as follows. Generic sertraline or escitalopram costs USD 30 to 120 per patient-year across emerging and developed pharmacies. Branded Zoloft or Cipralex lands at USD 250 to 600 a year where brand loyalty survives, mainly in Japan, China and private markets. Benzodiazepines sit at USD 20 to 90 a year as generics. A 12 to 16 session CBT course costs USD 900 to 2,400 privately in the United States and about USD 700 to 1,500 in Western Europe at public tariffs. Freespira, a 28-day breathing programme with two 17-minute sessions a day, sells for about USD 2,000 out of pocket.

Regional spend per treated patient-year follows the same pattern: USD 564.1 in North America, USD 256.7 in Europe, USD 85.8 in Latin America, USD 61.8 in Asia Pacific and USD 52.0 in the Middle East and Africa. Agoraphobia treatment pricing therefore rises fastest where therapy replaces tablets, not where tablet prices move.

Which companies sell agoraphobia medicines and exposure therapy tools?

The agoraphobia treatment market is fragmented: Douglas Insights estimates that the top-three branded sellers, Viatris, Lundbeck and Freespira, hold about 5.9% of 2025 value, because generics and therapist fees make up most spending. Viatris leads with an estimated 3.7% share.

Viatris, which distributes Zoloft, reported Zoloft sales of USD 188.1 million, Effexor USD 189.6 million and Xanax USD 100.4 million in the first nine months of 2025 in its third-quarter 2025 results filed with the SEC. Those brands serve depression and other anxiety disorders too; Douglas Insights attributes about 13% of their annualised USD 637.5 million to panic disorder with agoraphobia, roughly USD 82.9 million, or 3.7% of the market. H. Lundbeck reported DKK 1.57 billion of Cipralex and Lexapro (escitalopram) revenue for the same nine months, and its share of agoraphobia value is about 1.9% on the same attribution method.

Freespira, cleared by the FDA under 510(k) K180173, sells a capnometry-guided breathing device for panic disorder and holds about 0.3%. OxfordVR makes gameChangeVR, which the National Institute for Health and Care Excellence (NICE) allows in the NHS for severe agoraphobic avoidance in psychosis while evidence is gathered, delivered in about 6 weekly 30-minute sessions. Amelia Virtual Care and XR Therapeutics supply VR exposure libraries that NICE recommends for agoraphobia research use. Generic manufacturers of sertraline, escitalopram and alprazolam, plus thousands of independent psychologists, hold the remaining 94.1% of value.

Which region adds the most agoraphobia patients to treatment by 2035?

North America is the largest agoraphobia treatment region at USD 913.8 million in 2025, but Asia Pacific grows fastest at 5.12% a year to USD 798.4 million by 2035, overtaking Europe. Asia Pacific already holds 7.84 million of the 15.07 million treated patient-years.

North America earns 41.3% of value at USD 913.8 million and grows 3.08% a year to USD 1.24 billion, because therapy-heavy care pushes spend to USD 564.1 per patient-year. Europe holds USD 593.0 million and grows 2.71% to USD 774.8 million, held back by low generic prices but supported by publicly funded talking therapy. Asia Pacific, at USD 484.6 million, grows fastest because treated volume in China, India and Southeast Asia rises from a very low base as psychiatric services expand. Latin America reaches USD 190.1 million from USD 126.1 million at 4.19% a year. The Middle East and Africa is the wildcard: USD 95.2 million in 2025, rising at 4.37% to USD 146.0 million, with upside if Gulf insurers widen mental health benefits.

How many adults with agoraphobia receive any treatment each year?

About 15.07 million adults receive agoraphobia treatment in a year, out of 54.6 million with past-year symptoms, so roughly 39.5 million go without care. The untreated pool is nearly 3 times the treated one and is the agoraphobia treatment market’s largest source of future volume.

Douglas Insights counts the pool from four steps: 8.2 billion people, an adult share of 74%, 0.9% past-year prevalence from the NIMH agoraphobia statistics and a 27.6% treated rate. Women carry slightly more risk: NIMH reports past-year rates of 0.9% for women and 0.8% for men, and 2.4% of US adolescents have had agoraphobia at some point, all with severe impairment. Adolescents are a small share of today’s treatment spend, but school referrals and the 2025 extension of breathing-device clearance to ages 13 to 17 make them the fastest-growing patient group.

How do breathing devices and VR exposure headsets change agoraphobia care?

Digital therapeutics and VR exposure earn USD 108.4 million in 2025, just 4.9% of agoraphobia treatment value, yet they remove the clinic visit that agoraphobia patients avoid. Douglas Insights expects the slice to more than triple to USD 381.3 million by 2035.

Two device models compete. Capnometry-guided breathing, as in Freespira, trains patients to hold end-tidal carbon dioxide steady over 28 days at home. VR exposure, as in gameChangeVR, places the patient in a virtual bus, shop or street with a coach, and NICE describes a course of 6 weekly 30-minute sessions. Software is cheap to copy, so price falls as volume grows; the slice adds value through reach, not margin. Our AI in Mental Health Market report covers the conversational tools that now deliver exposure homework between sessions.

Which rules govern benzodiazepine prescribing and VR therapy for agoraphobia?

Agoraphobia treatment is governed by 3 sets of rules: medicine labels and Boxed Warnings, controlled-substance prescribing law, and health technology assessment for digital tools. In the United States, benzodiazepines are controlled medicines, so the 31 December 2026 telemedicine deadline matters for 13.8% of value.

The FDA label for Zoloft lists panic disorder among six indications, with a 25 mg starting dose that may rise to 200 mg a day, and Viatris Specialty is named as distributor. Clinical reviews treat SSRIs as first-line for panic disorder and agoraphobia alike, so the panic disorder indication carries most agoraphobic prescribing. Benzodiazepines carry the strengthened 2020 Boxed Warning on abuse, dependence and withdrawal, issued by the FDA. In England, NICE issues early value assessments for digital tools; its resource impact report for VR therapy notes that licence fees are commercial in confidence and that about 2 in 3 people with psychosis struggle with agoraphobia.

What if the agoraphobia treatment gap closes faster or slower than the 2035 base case?

The agoraphobia treatment market reaches USD 3.15 billion in 2035 in the base case, USD 2.76 billion if volume and price slow, and USD 3.63 billion if the treatment gap closes faster. One extra point of yearly volume growth adds about USD 320 million to the 2035 value.

The base case combines 2.62% volume and 0.94% price growth. The slower case uses 1.71% volume and 0.52% price, the path if remote controlled-substance prescribing lapses after 31 December 2026 and therapist supply stalls; it ends at USD 2.76 billion, a 2.24% CAGR. The faster case uses 3.64% volume and 1.38% price, the path if the HHS and DEA flexibilities become permanent and VR exposure wins reimbursement; it ends at USD 3.63 billion, a 5.07% CAGR. Published forecasts for this market run from about 3.2% to 7.35% a year, so our 3.58% sits in the lower third, because we price most volume at generic SSRI levels.

Douglas Exclusive: the Agoraphobia Treatment Access Register

The Agoraphobia Treatment Access Register is a Douglas Insights model, not an official registry, built from 11 inputs. They are the UN population count, NIMH prevalence and severity rates, the WHO treated share, the HHS telemedicine count, the FDA benzodiazepine data, two company filings, the Freespira and NICE treatment protocols, and our two regional price grids. It shows where agoraphobia treatment spending and treated patients sit.

The register’s finding is a mismatch. Asia Pacific holds 52% of treated agoraphobia patients but only 21.9% of value, while North America holds 10.7% of patients and 41.3% of value. Spend per patient-year differs by a factor of 10.8 between North America and the Middle East and Africa. Closing even a fifth of that gap through therapy access, not tablet pricing, is the largest single lever in the forecast.

How we built the agoraphobia treatment model, step by step?

The agoraphobia treatment model multiplies 15.07 million treated patient-years by USD 146.8, giving USD 2.21 billion in 2025, then compounds 2.62% volume and 0.94% price growth for 10 years to USD 3.15 billion. Five regions and five treatment types each reconcile to that total.

Volume: 8.2 billion people x 74% adults x 0.9% prevalence = 54.6 million cases; x 27.6% treated = 15.07 million patient-years. Price: five regional spend grids weighted by patients give USD 146.8. Douglas Insights calculates the 2026 value at USD 2.29 billion. We counted 5 regions, 5 treatment types, 6 companies and 6 published forecasts, 22 data points in all. Cross-check one: Viatris and Lundbeck attributed revenue of about USD 125 million equals 5.6% of value, close to the 5.9% top-three estimate. Cross-check two: published 2025 estimates run from USD 1.54 billion to USD 3.33 billion, and our USD 2.21 billion sits 9% below their midpoint. The full rules are on our methodology page.

Sources

1. National Institute of Mental Health Agoraphobia prevalence statistics (2025)
2. World Health Organization Anxiety disorders fact sheet (2026)
3. US Department of Health and Human Services HHS and DEA telemedicine extension for 2026 (2026)
4. US Food and Drug Administration Boxed Warning for benzodiazepine drug class (2020)
5. US SEC EDGAR Viatris third-quarter 2025 results (Form 8-K exhibit 99.1) (2025)
6. NICE VR technologies for severe agoraphobic avoidance in psychosis: resource impact (2025)
7. US Food and Drug Administration Zoloft prescribing information (2023)
8. US Food and Drug Administration Freespira 510(k) K180173 (2018)
9. United Nations World Population Prospects 2024 launch (2024)
10. H. Lundbeck A/S H. Lundbeck interim report, nine months 2025 (2025)